82
Participants
Start Date
July 10, 2024
Primary Completion Date
December 31, 2030
Study Completion Date
December 31, 2035
Paxalisib, Irinotecan, Temozolomide
Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
NOT_YET_RECRUITING
John Hunter Children's Hospital, Newcastle
RECRUITING
Sydney Children's Hospital, Randwick, Sydney
NOT_YET_RECRUITING
The Children's Hospital at Westmead, Sydney
RECRUITING
Queensland Children's Hospital, Brisbane
NOT_YET_RECRUITING
Women's and Children's Hospital, Adelaide
RECRUITING
Monash Children's Hospital, Melbourne
RECRUITING
Royal Children's Hospital, Melbourne
RECRUITING
Perth Children's Hospital, Perth
NOT_YET_RECRUITING
CHU Sainte Justine, Montreal
NOT_YET_RECRUITING
The Hospital for Sick Children, Toronto
NOT_YET_RECRUITING
BC Children's Hospital, Vancouver
Collaborators (2)
Children's Cancer Institute Australia (CCIA)
UNKNOWN
The Hospital for Sick Children
OTHER
Medical Research Future Fund
OTHER
Kazia Therapeutics Limited
INDUSTRY
C17 Council
OTHER
Australian & New Zealand Children's Haematology/Oncology Group
OTHER